Referent:innen

Dr Christian Palmes

Dr Christian Palmes

Bayer

Dr Steffen Groß

Dr Steffen Groß

Paul-Ehrlich-Institut (PEI)

Dr Line Lundsberg-Nielsen

Dr Line Lundsberg-Nielsen

NNE

Dr Martin Maus

Dr Martin Maus

Boehringer Ingelheim

Dr Andrea Staab

Dr Andrea Staab

Boehringer Ingelheim

Note: All times mentioned are CEST.

Zielsetzung

You will be updated on the latest regulatory developments and learn how to apply the respective paradigms in Pharmaceutical Development to be better able to design strategies for the implementation of Quality by Design (QbD) according to ICH Q8.

During this Live Online Training elements and methodologies associated with ICH Q8 will be discussed. All this will be illustrated with examples and case studies.

Hintergrund

The impact of ICH Q8, Q9, Q10, and Q11 is changing both the regulatory expectations and the strategies of Pharmaceutical Development. This impact will continue to grow, especially in view of the ICH Q12 Guideline.

The QbD concept described in ICH Q8 and ICH Q11 have to be seen as an overarching paradigm and an interdisciplinary approach across the product lifecycle. It also systematically emphasises enhanced product and process understanding throughout the product lifecycle.

Ideally, application of ICH Q8 and ICH Q11 elements already starts in the early design phase of a drug product where both patients’ needs and process design are considered. The QbD concept requires a comprehensive understanding of the chemical and physical nature of the individual active substance(s) and excipients, and of the way their attributes interact in the formulation and how they are impacted by the manufacturing process. During the design phase, it is important to establish the Quality Target Product Profile (QTPP), determine the Critical Quality Attributes (CQAs), identify Critical Process Parameters (CPPs) and Material Attributes (material CQAs) and to understand how the process parameters and material attributes affect the CQAs. The relationship between process inputs (material attributes and process parameters) and the CQAs is described in the Design Space and ensured during manufacturing with an enhanced control strategy, leading to improved process understanding, greater operational flexibility and opportunities for more efficient life cycle management activities. 

ICH Q8 combined with ICH Q12 will open the door to a powerful era of refined, modern and efficient pharmaceutical development and optimization for those companies who are ready to invest in this new paradigm.

Zielgruppe

This Live Online Training addresses scientists, engineers, managers and executives from Pharmaceutical and Biotech Development units and support functions to Manufacturing, including Quality Assurance and Technical/CMC Regulatory Affairs, who are involved in the implementation of ICH Q8 Elements.

Technical Requirements

We use WebEx for our live online training courses and webinars. At https://www.gmp-compliance.org/training/online-training-technical-information you will find all the information you need to participate in our trainings and you can check if your system meets the necessary requirements to participate. If the installation of browser extensions is not possible due to your rights in the IT system, please contact your IT department. WebEx is a standard nowadays and the necessary installation is fast and easy.

The presentations will be made available to you prior to the Live Online Training as PDF files. After the event, you will automatically receive your certificate of participation.

Programm

ICH Q8 Training Course - Live Online Training

Gesamtes Programm als PDF herunterladen

Programme Day 1
 
Introduction to QbD – Setting the Scene
  • Drug product development at a glance – from first in man to marketing authorization
  • Pharmaceutical QbD: Quo vadis?
  • Application of QbD principles to drug product development
QbD - Regulatory Perspective
  • Current state of PAT & QbD implementation and regulatory challenges
  • Quality by on-line (PAT) measurements
  • Real time release testing: general considerations
  • Going forward: ICH Q12 / Q13 / Q14
Quality Risk Management and Control Strategy
  • Objectives of Quality Risk Assessment (QRA) as part of development
  • Overview on risk assessment tools
  • Introduction to Process Risk Map
  • Introduction of risk-based control strategy development
Q&A Session 1
 
Case Study DoE
  • Why we use DoE in the pharmaceutical development
  • Example: DoE for formulation selection / optimization
  • Example: DoE for manufacturing process optimization
  • DoE vs “traditional” approach – when to use which
QbD Toolbox: DoE, PAT, Basic Statistics
  • Value-added use of QbD tools – generic approaches and tailored Solutions
  • Examples for different unit operations and variable problems
Q&A Session 2
 
 
Programme Day 2
 
Reports and Documentation
  • Development Reports
  • Transfer protocols and reports
  • Control Strategy and link to the submission dossier
How the QbD derived Control Strategy defines Process Validation
  • QbD and PAT as an enabler for gaining Process Understanding and designing the process and the control strategy, PV stage 1 (establishing the control strategy)
  • Different approaches to PV/PPQ depending on the type of control strategy, PV stage 2 (traditional, continuous process verification or hybrid approach used to verify the control strategy)
  • Ongoing/Continued Process verification, PV stage 3 (verifying the validity and robustness of the control strategy)
Process Validation – Case Study (Small Molecule Drug Product
Case study related to the previous presentation (PV stage 1 and 2)
  • Case example of a solid dosage form process enabled by a QbD approach
  • Establishing the control strategy: Examples of the application of PAT/RTRT
  • Validation of the process – verification of the control strategy
Ongoing Process Verification and Lifecycle Approach of a Process established from QbD Principles
  • Continuous process verification versus continued/ongoing process verification (PV stage 3)
  • Case study – the continuation of the example from above (PV stage 3)
  • ICH Q12, performance-based control and the link to PAT
  • Life cycle management of the product, process and control strategy opportunities for a product developed using of a QbD principles
Q&A Session 3

ECA-Member*: € 1690,-
Non ECA Member*: € 1890,-
EU/GMP Inspectorates*: € 945,-
APIC Member Discount*: € 1790,-

Alle Preise zzgl. MwSt. Wichtige Hinweise zur Umsatzsteuer.

* auch unkompliziert per Kreditkarte bezahlbar
American Express Visa Mastercard

icon
Weitere Termine vor Ort
Weitere Termine vor Ort nicht verfügbar
icon
Weitere Termine online
Weitere Termine online nicht verfügbar
icon
Aufzeichnung nicht verfügbar

Haben Sie noch Fragen?

Wir stehen Ihnen für weitere Auskünfte gerne zur Verfügung.

Frau mit Headset
Tel.: +49 6221 84 44 0
E-Mail: info@concept-heidelberg.de

Zurück

Teilnehmerstimmen - das sagen andere über unsere Seminare:

"Die Umsetzung mit Memberspot ist wirklich ausgezeichnet gelungen.
Es unterstützt die Wissensvermittlung und gewährleistet auch die richtige Durchführung des Kurses.”
Christian Wagener, WAGENER & CO. GmbH
GMP Basis-Einstiegsschulung (B 1) - Aufzeichnung Online Seminar, April 2024

„Danke für das tolle und interessante Seminar! Ich nehme mir fachlich total viel mit und habe viele tolle Menschen kennengelernt.“
Melanie Schifferer, DAIICHI SANKYO EUROPE GmbH
Batch Record Review (QS 23)
September 2024

Guter, breit gefächerter Überblick mit interessanten Verknüpfungen zur Praxis,
welche die Theorie super veranschaulicht.”
Marina Kicoranovic, Labor Hartmann GmbH
GMP/Basis-Einstiegsschulung (B 14), September 2023

Die Referenten waren sehr gut! Sie haben sehr klar gesprochen, nur sehr wenige englische Begriffe
verwendet (super) und waren sehr praxisbezogen.”
Astrid Gießler, Regierungspräsidium Karlsruhe
Live Online Seminar - Basiskurs Computervalidierung & Datenintegrität im GxP Umfeld (B 3), Juni 2023

Sehr guter Bezug zur Schulung für einen GMP-Anfänger. Habe mich sehr gut abgeholt gefühlt.”
Dr. Harald Werner, Infraserv GmbH & Co. Höchst KG
GMP-Basisschulung (B 1), Juni 2023

„Interessante Themen, gut vorgetragen, die eigenen Erfahrungen der Vortragenden helfen, dies noch besser nachzuvollziehen.“ „Gute Gestaltung der Workshops, das Zusammenarbeiten in Gruppen und der Austausch mit anderen hilft sehr.“
Manuela Seibert, Merck, GMP-Leadauditor/in (FA 2), April 2024

NEWSLETTER

Bleiben Sie informiert mit dem GMP Newsletter von Concept Heidelberg!

GMP Newsletter

Concept Heidelberg bietet verschieden GMP Newsletter die Sie auf Ihren Bedarf hin zusammenstellen können.

Hier können Sie sich kostenfrei registrieren.

Kontakt

Kontaktieren Sie uns

Haben Sie Fragen?

Concept Heidelberg GmbH
Rischerstraße 8
69123 Heidelberg

Tel. :+49622184440
Fax : +49 6221 84 44 84
E-Mail: info@concept-heidelberg.de

zum Kontaktformular